Equity Profile

TYRA

Tyra Biosciences, Inc.

Health CareBiotechnology$1.9B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal positive momentum in Tyra's business operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the health care sector, Tyra is working on targeted therapies that aim to improve patient outcomes, making it a significant player in the ongoing fight against cancer.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, which was slightly below expectations. The stock reacted positively the next day, gaining 3.79%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Tyra's upcoming earnings report, especially given the company's recent performance and the potential for clinical updates.

Bull Case

If Tyra can show better-than-expected EPS and positive news from clinical trials, it could lead to a significant stock rally.

Bear Case

Conversely, if the company reports a larger-than-expected loss or negative updates on clinical trials, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for clinical trial results?

Investors will be keen to understand how soon they can expect results, as this could impact future revenue and stock performance.

How does management plan to address the recent EPS losses?

Any concrete plans to improve profitability will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of Tyra's upcoming clinical trial results, which could significantly shift investor sentiment.

Supporting Evidence

The options market is pricing a 9.39% move, indicating higher volatility than usual, which may reflect underlying uncertainty.

Tyra's recent stock performance suggests that investors are cautiously optimistic despite the EPS losses.

Key Risk

If clinical trial results exceed expectations, it could lead to a substantial upward revision in the stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to manage costs while advancing its clinical programs.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.70 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests a potential stock increase of around +0.18%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity.

Miss

A miss could lead to a decline, with history suggesting an average drop of +0.10% following negative surprises.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Any commentary on cost management strategies.
3Details on partnerships or collaborations that may influence growth.
4Insights into the competitive landscape and how Tyra plans to differentiate itself.
5Management's outlook on future revenue streams.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal positive momentum in Tyra's business operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, which was slightly below expectations. The stock reacted positively the next day, gaining 3.79%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Tyra's upcoming earnings report, especially given the company's recent performance and the potential for clinical updates.

Bull Case

If Tyra can show better-than-expected EPS and positive news from clinical trials, it could lead to a significant stock rally.

Bear Case

Conversely, if the company reports a larger-than-expected loss or negative updates on clinical trials, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for clinical trial results?

Investors will be keen to understand how soon they can expect results, as this could impact future revenue and stock performance.

How does management plan to address the recent EPS losses?

Any concrete plans to improve profitability will be critical for investor confidence moving forward.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the impact of Tyra's upcoming clinical trial results, which could significantly shift investor sentiment.

Supporting Evidence

The options market is pricing a 9.39% move, indicating higher volatility than usual, which may reflect underlying uncertainty.

Tyra's recent stock performance suggests that investors are cautiously optimistic despite the EPS losses.

Key Risk

If clinical trial results exceed expectations, it could lead to a substantial upward revision in the stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to manage costs while advancing its clinical programs.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.70 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests a potential stock increase of around +0.18%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity.

Miss

A miss could lead to a decline, with history suggesting an average drop of +0.10% following negative surprises.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Any commentary on cost management strategies.
3Details on partnerships or collaborations that may influence growth.
4Insights into the competitive landscape and how Tyra plans to differentiate itself.
5Management's outlook on future revenue streams.